side effect difference between semaglutide and tirzepatide vs. Tirzepatide: Which Is the Best at Managing Weight Loss? Semaglutide vs Tirzepatide - Key

An NDA filing is expected in late 2026 or early 2027, with FDA approval potentially in late 2027 or the first half of 2028

Scenario 2 (delayed or limited approval): If cardiovascular safety concerns emerge (glucagon agonism theoretically increases heart rate and may elevate blood pressure in susceptible individuals) or gastrointestinal tolerability limits real-world adherence, retatrutide remains investigational

Common side effects include nausea, vomiting, and diarrhoea

If you feel ready to go deeper, beyond one-size-fits-all programs, beyond symptom management, toward true regenerative transformation, our team is here